Genedrive plc (LSE:GDR) has confirmed that its Genedrive® MT-RNR1 ID Kit is now being deployed across NHS Scotland, marking a major step in efforts to prevent antibiotic-induced hearing loss in newborns treated in neonatal intensive care. Backed by NHS Greater Glasgow and Clyde, the rollout is expected to materially improve clinical decision-making by enabling rapid genetic screening, helping clinicians tailor treatments and ultimately supporting better long-term outcomes for infants and their families.
Financially, Genedrive continues to grapple with the challenge of turning revenue momentum into sustained profitability. While the balance sheet remains healthy, valuation indicators are constrained by the company’s loss-making status, and technical signals currently point to downward pressure on the share price. Even so, recent operational progress strengthens Genedrive’s strategic position and may improve its prospects over time.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company focused on developing rapid, cost-efficient point-of-care solutions that help clinicians personalise treatment decisions. Its core technologies—including the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit—provide fast genetic insights designed to guide medication choices and dosing, particularly in urgent or emergency care settings.









